Strategic Partnerships Carrick has a history of clinical trial collaborations with big pharma (Arvinas, Pfizer, Menarini) to evaluate combinations like samuraciclib with endocrine therapies. This indicates a warm channel for BD outreach around co-development, partner-justified trials, or licensing discussions to expand their trial networks and accelerate validation in breast cancer and other aggressive cancers.

Clinical Trial Growth With a recent focus on trial collaborations and a high-value HR+, HER2- breast cancer program (samuraciclib), there is potential to upsell CRO services, patient recruitment partnerships, biomarker validation, and companion diagnostic development to support multi-arm, multi-center trials.

Financing Momentum Pfizer-led investment and a substantial Series C funding round signal strong investor confidence and willingness to fund advanced oncology programs. This creates opportunities for advisory services, strategic partnerships, and co-development financing discussions to accelerate pipeline milestones.

Specialized Oncology Focus Carrick targets first-in-class, driver-mechanism therapies for aggressive cancers with personalized tumor tailoring. This presents a sales angle for technologies that support precision oncology, such as molecular profiling, trial-enabling analytics, and data platforms that streamline patient stratification and monitoring.

Global Research Network By linking clinicians and scientists across leading research institutes and hospitals, Carrick is positioned to benefit from services that expand site networks, patient access programs, and centralized data coordination, offering scalable solutions for site management, regulatory support, and clinical data management.